Allworth Financial’s Atossa Therapeutics ATOS Stock Holding History

Allworth Financial’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-46	Closed	-$242	–	5171
2026 Q1	$242	Sell	46 -1	-2%	-$6	﹤0.01%	4890
2025 Q4	$415	Hold	47	–	–	﹤0.01%	4569
2025 Q3	$609	Hold	47	–	–	﹤0.01%	4384
2025 Q2	$583	Hold	47	–	–	﹤0.01%	4096
2025 Q1	$515	Hold	47	–	–	﹤0.01%	3666
2024 Q4	$673	Hold	47	–	–	﹤0.01%	3523
2024 Q3	$1.07K	Hold	47	–	–	﹤0.01%	3195
2024 Q2	$941	Hold	47	–	–	﹤0.01%	3182
2024 Q1	$1.26K	Hold	47	–	–	﹤0.01%	3001
2023 Q4	$618	Hold	47	–	–	﹤0.01%	3081
2023 Q3	$518	Hold	47	–	–	﹤0.01%	3033
2023 Q2	$885	Hold	47	–	–	﹤0.01%	2766
2023 Q1	$509	Hold	47	–	–	﹤0.01%	2836
2022 Q4	$371	Hold	47	–	–	﹤0.01%	2697
2022 Q3	$1K	Hold	47	–	–	﹤0.01%	2305
2022 Q2	$1K	Hold	47	–	–	﹤0.01%	2085
2022 Q1	$1K	Hold	47	–	–	﹤0.01%	1875
2021 Q4	$1K	Hold	47	–	–	﹤0.01%	1784
2021 Q3	$2K	Hold	47	–	–	﹤0.01%	1656
2021 Q2	$4K	Hold	47	–	–	﹤0.01%	1239
2021 Q1	$1K	Buy	+47	New	+$1.72K	﹤0.01%	1366

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allworth Financial's ATOS Position: Q2 2026 in Review

Allworth Financial sold out of Atossa Therapeutics (ATOS) in Q2 2026, closing a stake of 46 shares — an estimated $242 sold.

Allworth Financial first reported a position in ATOS in Q1 2021 and held it in 21 quarters. The position peaked at $4K in Q2 2021. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

Allworth Financial reported no remaining Atossa Therapeutics position as of Q2 2026 after selling out during the quarter.
Allworth Financial sold 46 Atossa Therapeutics shares in Q2 2026, an estimated $242.
Allworth Financial first reported a position in Atossa Therapeutics in Q1 2021 and held it in 21 quarters.
Allworth Financial's Atossa Therapeutics position peaked at $4K in Q2 2021.
31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.